光激酶B转移阻断剂LXY18在恶性细胞中选择性地触发了线粒性灾难
Julia Kalashova1,2, Chenglu Yang1,2, Hongmei Li1,2
1Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.
PloS one
|October 30, 2023
概括
新型化合物LXY18针对AURKB的局部化,诱导癌细胞死亡而不会伤害正常细胞. 这表明LXY18是一个有前途的癌症治疗和研究工具.
科学领域:
- 细胞生物学 细胞生物学
- 分子瘤学分子瘤学
- 药物发现 药物发现 药物发现
背景情况:
- 极光激酶B (AURKB) 是一种关键的线粒调节剂,在许多癌症中过度表达.
- 准AURKB是癌症治疗的一种策略.
- LXY18是一种新的AURKB局部化的小分子抑制剂.
研究的目的:
- 为了研究LXY18.18的抗癌作用.
- 为了确定LXY18.18的作用机制.
- 评估LXY18作为癌症治疗的潜力.
主要方法:
- 用LXY18治疗各种癌症和非转化细胞系.
- 评估细胞亡,细胞循环进展和线粒细胞停止.
- 对AURKB局部化和激酶活性的分析.
- 对抗AURKB激酶抑制剂的癌细胞敏感性的评估.
主要成果:
- LXY18在癌细胞中诱导了亡,但在非转化细胞中没有.
- 亡是p53独立的,由长期的线粒细胞停止引发.
- 抗AURKB激酶抑制剂的癌细胞对LXY18.18敏感.
- LXY18没有抑制AURKB或相关局部化因子的激酶活性.
结论:
- 通过破坏AURKB局部化,LXY18表现出选择性的抗癌活性,导致线粒体停止和细胞死亡.
- LXY18代表了一种潜在的新型癌症药物候选者,也是研究线粒细胞调节的宝贵工具.
更多相关视频
07:14Live Cell Imaging to Assess the Dynamics of Metaphase Timing and Cell Fate Following Mitotic Spindle Perturbations
Published on: September 20, 2019
8.2K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.1K
相关概念视频
Anaphase Promoting Complex
2.9K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.9K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Destabilization of Microtubules
2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
